XML 30 R21.htm IDEA: XBRL DOCUMENT
v3.26.1

Leases | 6 Months Ended
--- | ---
Apr. 30, 2026
Leases [Abstract] |
Leases | 13. Leases The Company’s leases are comprised of operating leases for office and lab space. On December 29, 2022, the Company signed a lease for approximately 10,620 square feet of new laboratory and office space at 4868 Rue Levy, Montreal, QC. The term of the lease is for 10 years, beginning on the commencement date, and requires an annual initial base rent of $36.50 CAD per square foot, which is subject to annual increases of 2%. The lease commenced in November 2023. Upon commencement the Company recognized an initial lease liability and corresponding right of use asset of $1.4 million. On January 1, 2024, enGene USA, Inc. entered into a lease agreement, in which the Company is sub-leasing approximately 6,450 square feet of office space located at 200 Fifth Avenue, Waltham, MA. The Company will make an aggregate amount of base rental payments of $0.5 million under the initial term of the lease, which is set to expire on December 30, 2026 and does no t have an option to renew. Upon commencement, the Company recognized an initial lease liability and corresponding right of use asset of $0.4 million. On June 4, 2025, enGene USA, Inc. entered into a lease agreement, pursuant to which the Company agreed to lease approximately 26,335 square feet of office space located at 99 High Street, Boston, Massachusetts. The Company is expected to make an aggregate amount of base rental payments of $10.6 million, under the initial term of the lease, which is set to expire in November 2030. In connection with the lease, enGene Therapeutics Inc. has delivered a guaranty, dated June 4, 2025, pursuant to which the Company guaranteed enGene USA's payment and performance. The lease commenced in June 2025 and upon commencement, the Company recognized an initial lease liability of $6.4 million and corresponding right of use asset of $6.5 million. During the three and six months ended April 30, 2026 and 2025, the components of operating lease cost were as follows, and are reflected in general and administrative expenses and research and development expenses, as determined by the underlying activities:
|  | Three Months Ended April 30, |  |  | Six Months Ended April 30, |
|  | 2026 |  |  | 2025 |  |  | 2026 |  |  | 2025 |
Lease Cost: |  |  |  |  |  |  |  |  |  |  |  |
Operating lease cost |  | $ | 585 |  |  | $ | 115 |  |  | $ | 1,183 |  |  | $ | 230 |
Variable operating lease cost |  |  | — |  |  |  | — |  |  |  | — |  |  | — |
Total operating lease cost |  | $ | 585 |  |  | $ | 115 |  |  | $ | 1,183 |  |  | $ | 230 |
Maturities of the Company's operating lease liabilities as of April 30, 2026 are as follows:
2026 |  | $ | 1,250 |
2027 |  |  | 2,397 |
2028 |  |  | 2,415 |
2029 |  |  | 2,463 |
2030 |  |  | 2,509 |
Thereafter |  |  | 1,105 |
Total |  |  | 12,139 |
Less: Interest |  |  | (3,891 | )
Total lease liability |  | $ | 8,248 |

X
- References No definition available. + Details
Name: | us-gaap_LeasesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent + Details
Name: | us-gaap_LesseeOperatingLeasesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration